WallStSmart
NRXP

NRX Pharmaceuticals Inc

NASDAQ: NRXP · HEALTHCARE · BIOTECHNOLOGY

$2.98
+2.41% today

Updated 2026-04-30

Market cap
$100.19M
P/E ratio
P/S ratio
81.79x
EPS (TTM)
$-1.34
Dividend yield
52W range
$2 – $4
Volume
0.9M

NRX Pharmaceuticals Inc (NRXP) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+49.8%
Last 4 quarters
Revenue YoY growth
+24475.0%
Most recent quarter
EPS YoY growth
+123.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+8.8%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+36.2%
2026-03-24
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-24$0.18+329.1%$1.77$2.41+36.2%
2025-11-14$-0.27+48.1%$2.59$2.11-18.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.08$0.18+329.1%$983000.00+24475.0%
2025-09-30$-0.52$-0.27+48.1%$242000.00
2025-06-30$-0.53$-0.98-84.9%
2025-03-31$-0.53$-0.34+35.8%$4000.00-50.0%
2024-12-31$-0.37$-0.77-108.1%$4000.00-50.0%
2024-09-30$-0.64$-0.15+76.6%
2024-06-30$-0.69$-0.67+2.9%
2024-03-31$-0.55$-0.74-34.5%$8000.00
2023-12-31$-0.70$-0.50+28.6%$8000.00
2023-09-30$-0.11$-0.07+36.4%
2023-06-30$-0.14$-0.12+14.3%
2023-03-31$-0.14$-0.16-14.3%

Frequently asked questions

Has NRX Pharmaceuticals Inc beaten earnings estimates?
NRX Pharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +49.8% over the last 4 quarters.
How does NRXP stock react to earnings?
NRXP stock has moved an average of +8.8% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is NRX Pharmaceuticals Inc's revenue growth rate?
NRX Pharmaceuticals Inc reported year-over-year revenue growth of +24475.0% in its most recent quarter, with EPS growing +123.8% year-over-year.